Compare Jumia Technologies AG - ADR (JMIA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs BIO-TECHNE Corp — how do they compare? Jumia Technologies AG - ADR trades at $6.45 (market cap $805.04M), while BIO-TECHNE Corp trades at $71.63 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 14× Jumia Technologies AG - ADR's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| JMIA | TECH | |
|---|---|---|
Market Cap | $805.04M | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $72.12 |
52-Week Low | $4.45 | $43.31 |
Enterprise Value | $752.14M | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $6.50, down 0.15% on the day, with a bearish technical signal from moving averages. Revenue grew to $188.93M in 2025, but net losses narrowed to -$61.55M, showing progress toward the 2027 profitability target. Recent news highlights strong Q1 2026 GMV growth and strategic expansions, including a Starlink partnership. The stock faces headwinds from persistent negative cash flow from operations and high valuation multiples like a P/B of 61.59.
The outlook is cautiously optimistic, with 71% analyst buy ratings supporting recovery potential, but risks include sustained losses, competitive pressures in African e-commerce, and macroeconomic volatility. Investors should weigh the path to profitability against execution challenges.
Bio-Techne (TECH) trades at $71.72, down 0.55% on the day, near the $73.00 per share cash acquisition offer from Merck KGaA announced on June 25, 2026 (Reuters). The stock shows a bullish technical signal with moving averages supporting an uptrend, while fundamentals reveal high valuation multiples (P/E of 103.03) and a recent decline in net income margin to 9.05% in 2025. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
The investment outlook is heavily influenced by the pending acquisition, offering a clear near-term upside to the $73.00 bid price. Risks include shareholder litigation questioning the deal's fairness and potential regulatory hurdles. Analyst consensus is evenly split between Buy and Hold, reflecting uncertainty around deal completion versus fundamental valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
